Entolimod May be a Promising Treatment Option for Many Solid Tumors
A collaborative team of researchers led by Alex A. Adjei, MD, PhD, FACP, of Roswell Park Cancer Institute (RPCI) shared results from the first clinical study of the anticancer effects of the novel agent entolimod at the American Society of Clinical Oncology’s 51st Annual Meeting in Chicago. Their findings confirm preclinical evidence that the agent, which is derived from salmonella flagellin, is worthy of further investigation as treatment for some of the most common and most resilient solid-tumor cancers.
Toll-like receptors are a family of proteins that help generate immune responses against cancer and other pathogens. Entolimod, the lead drug candidate of Cleveland BioLabs Inc., of Buffalo, NY, activates toll-like receptor 5 (TLR5) and has been shown to have immunotherapeutic effects in preclinical cancer models.
Hatoon Bakhribah, MD, a Drug Development Fellow in Roswell Park’s Department of Medicine, presented the results of this Phase I clinical study at ASCO. Dr. Adjei and colleagues evaluated the agent’s safety, tolerability, pharmacokinetics, immunoactivity, and preliminary antitumor activity in patients with a number of different advanced cancers, including colorectal, non-small-cell lung, anal and urothelial bladder tumors.
Among 26 participants in this dose-escalation study, 8 patients had stable disease for more than 6 weeks following treatment with entolimod, and 3 patients maintained disease stability for longer than 12 weeks. The tolerability profile in patients with advanced cancer was similar to that observed in two previous studies in 150 healthy volunteers who received entolimod in a similar dose range. Mild-to-severe but manageable side effects, such as hypotension and hyperglycemia, all of them anticipated effects of TLR5 activation, were observed in several patients. The results corroborated preclinical findings and suggest that entolimod should be further studied as an immunotherapeutic anticancer agent.
“Our findings are encouraging, as they suggest that entolimod can be safely combined with other chemotherapeutic, targeted, or immunotherapeutic agents as treatment for advanced and very hard-to-treat cancers,” noted Dr. Adjei, who is Senior Vice President of Clinical Research and the Katherine Anne Gioia Chair in Cancer Medicine at Roswell Park. “We’ve identified a recommended dosing schedule for future studies.”
The study, A phase I study of the toll-like receptor 5 (TLR5) agonist, entolimod, in patients with advanced cancers, is abstract 3063 and was presented on board no. 389 during the Developmental Therapeutics—Immunotherapy poster session on Saturday, May 30.
The mission of Roswell Park Cancer Institute (RPCI) is to understand, prevent, and cure cancer. Founded in 1898, RPCI is one of the first cancer centers in the country to be named a National Cancer Institute-designated comprehensive cancer center and remains the only facility with this designation in Upstate New York. The Institute is a member of the prestigious National Comprehensive Cancer Network, an alliance of the nation’s leading cancer centers; maintains affiliate sites; and is a partner in national and international collaborative programs. For more information, visit www.roswellpark.org, call 1-877-ASK-RPCI (1-877-275-7724) or email firstname.lastname@example.org. Follow Roswell Park on Facebook and Twitter.
Total Page Views: 361